May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
0.1% Cyclosporine Eye Drops for Patients With Vernal Keratoconjunctivitis
Author Affiliations & Notes
  • H. Fujishima
    Department of Ophthalmology, Keio Univ School of Medicine, Shinjuku-Ku, Japan
  • Y. Takano
    Department of Ophthalmology, Kawasaki Municipal Hospital, Kawasaki, Japan
  • D. Murat
    Department of Ophthalmology, Keio Univ School of Medicine, Shinjuku-Ku, Japan
  • M. Tanaka
    Department of Ophthalmology, Keio Univ School of Medicine, Shinjuku-Ku, Japan
  • N. Okada
    Department of Ophthalmology, Keio Univ School of Medicine, Shinjuku-Ku, Japan
  • A. Igarashi
    Department of Ophthalmology, Keio Univ School of Medicine, Shinjuku-Ku, Japan
  • K. Tsubota
    Department of Ophthalmology, Keio Univ School of Medicine, Shinjuku-Ku, Japan
  • K. Fukagawa
    Department of Ophthalmology, Keio Univ School of Medicine, Shinjuku-Ku, Japan
  • Footnotes
    Commercial Relationships H. Fujishima, None; Y. Takano, None; D. Murat, None; M. Tanaka, None; N. Okada, None; A. Igarashi, None; K. Tsubota, None; K. Fukagawa, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5845. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Fujishima, Y. Takano, D. Murat, M. Tanaka, N. Okada, A. Igarashi, K. Tsubota, K. Fukagawa; 0.1% Cyclosporine Eye Drops for Patients With Vernal Keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5845.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Cyclosporine, which has been implicated in immuno suppressive drugs, is known to effective for the treatment of allergic diseases. We have studied the efficacy of treatment for patients with vernal keratoconjunctivitis (VKC) of newly developed three times daily topical application of 0.1% cyclosporine.

Methods:: We evaluated 30 patients with severe treat-resistant VKC with corneal complications for six month. Some of the patients suffer atopic dermatitis. 10 patients treated with 0.1% cyclosporine alone and other patients added 0.1% cyclosporine with anti-allergic eye drops and/or steroid, which had been used before starting 0.1% cyclosporine. Every month, the patients were evaluated for symptoms including itching, discharge, tearing, photophobia, foreign body sensation, pain. We observed signs such as conjunctival injection, edema, follicle, papilla formation, and corneal complications. Visual acuity and intraocular pressure were measured.

Results:: Symptoms were all improved by the end of 6 month period. Signs of edema, follicle, papilla and giant papilla formation, and corneal complications were improved from 1 month after treatment. Number of patients who used steroid was decreased. Visual acuity was improved and intraocular pressure was not increased. Side effects of one case of hordeolum and one case of herpes keratitis recurrence was observed. They were treated completely with adequate drugs.

Conclusions:: 0.1% Cyclosporine eye drops with or without conventional topical treatment was effective for patients with VKC. No other severe complications were observed.

Keywords: conjunctivitis • cyclosporine • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×